Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to -$1.85.

  • Agios Pharmaceuticals' EPS (Basic) fell 755.81% to -$1.85 in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.11, marking a year-over-year decrease of 16030.53%. This contributed to the annual value of -$7.12 for FY2025, which is 16003.37% down from last year.
  • Latest data reveals that Agios Pharmaceuticals reported EPS (Basic) of -$1.85 as of Q4 2025, which was down 755.81% from -$1.78 recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' EPS (Basic) ranged from a high of $26.95 in Q1 2021 and a low of -$1.93 during Q2 2025
  • Over the past 5 years, Agios Pharmaceuticals' median EPS (Basic) value was -$1.56 (recorded in 2021), while the average stood at $0.91.
  • Per our database at Business Quant, Agios Pharmaceuticals' EPS (Basic) soared by 229105.69% in 2021 and then tumbled by 35671.64% in 2023.
  • Over the past 5 years, Agios Pharmaceuticals' EPS (Basic) (Quarter) stood at $0.07 in 2021, then soared by 923.5% to $0.67 in 2022, then plummeted by 356.72% to -$1.72 in 2023, then dropped by 0.0% to -$1.72 in 2024, then fell by 7.56% to -$1.85 in 2025.
  • Its EPS (Basic) was -$1.85 in Q4 2025, compared to -$1.78 in Q3 2025 and -$1.93 in Q2 2025.